ClinicalTrials.gg
Not yet recruitingNCT07893054Updated Oct 23, 2026

A First-in-human Clinical Trial to Test if the Investigational Drug BNT3219 is Safe and Potentially Beneficial for People With Advanced Solid Tumors When Given Alone or Together With Other Investigational Drugs

A Phase 1 interventional study of BNT3219 in Advanced Solid Tumors, sponsored by BioNTech SE. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by BioNTech SE · Phase 1, Interventional, and Treatment

Updated Oct 23, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
207
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will test BNT3219 (also known as PM1092) in adults with advanced solid tumors whose cancer has progressed after available standard treatments. It is the first study of BNT3219 in people, and it will test different dose levels to identify safe and tolerable doses. The study will also examine how the treatment moves through the body, whether the immune system reacts to them, and whether it shows signs of shrinking or controlling tumors.

Read the detailed description

This study will initiate with Part A which will consist of a dose escalation and dose expansion of BNT3219 monotherapy. The dose expansion will be conducted in some specific indications with the recommended phase II dose (RP2D) generated from the dose escalation.

The sponsor will analyze all available data from Part A and may decide to continue the study with Part B to investigate BNT3219 in combination with other investigational therapies.

There will be a Screening Period, a Treatment Period, and a Follow-up Period (including an end-of-treatment visit, two safety follow-up visits, and a survival follow-up period with regular visits).

Participants will remain in the survival follow-up period until death, lost to follow-up, withdrawal of consent, or until the sponsor terminates the study, whichever occurs first.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Bispecific antibody
  • Human immunoglobulin G (IgG) 1 bispecific antibody
  • Immunotherapy
03

In context

Lead sponsor

BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Are ≥18 years of age at the time of the form signature. Local laws will be followed if the age of consent is older.
  • Have or cytologically confirmed locally advanced, recurrent, or solid tumors which have progressed after at least one available standard therapy; or for whom the standard therapy is considered to be ineffective, inappropriate or intolerable, or for whom no standard treatment is available.
  • Must be willing to provide a tissue sample, archival or fresh, during the screening period. An less than 2 years old is only acceptable if biopsy is not feasible due to safety concerns.
  • Have at least one based on v1.1.
  • Have an performance status of 0 (fully active, able to carry out all pre-disease activities without restriction) or 1 (unable to perform physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature).
  • Have a predicted of ≥3 months.
  • Have a of ≥50% by either echocardiogram or multi-gated acquisition scan within 28 days prior to first dose of study treatment.
  • Have an adequate liver, renal, hematological, and coagulation function as defined by the protocol.
  • Have recovered to Grade 1 or baseline from adverse reactions related to prior anticancer therapy except for toxicity that the investigator determined to have no safety risk, such as alopecia, Grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, etc.
  • The investigator considers discontinuation of protocol-specified anticancer therapies and restricted medications with protocol-specified prior to the first dose of study treatment as medically acceptable.

Key Exclusion Criteria:

  • Have an active infection (e.g., bacterial or fungal infections or tuberculosis) requiring systemic IV treatment (e.g., severe pneumonia, bacteremia, sepsis), or any uncontrolled infection within 14 days prior to the first dose of study treatment.
  • Have active central nervous system metastases and/or carcinomatous meningitis as defined in the protocol.
  • Participants at imminent risk for spinal cord compression or are not eligible.
  • Have unstable pleural effusion or ascites requiring thoracentesis or paracentesis within 14 days prior to initiation of study treatment.
  • Have active, or a history of, pneumonitis requiring treatment with , or has active, or a history of, interstitial lung disease. Those with a history of pulmonary fibrosis or currently diagnosed with severe lung diseases such as interstitial pneumonia, pneumoconiosis, chemical pneumonitis, or any other condition resulting in significant impairment in lung function.
  • Have pulmonary complications including, but not limited to, , restrictive lung disease, lung injury accompanied with disease/connective tissue disorders.
  • Have a history of severe cardiovascular disease as defined in the protocol.
  • Have a history of serious Grade ≥3 immune-related adverse events that led to treatment discontinuation of a prior immunotherapy. Participants with a history of Grade ≥3 that did not lead to treatment discontinuation of a prior immunotherapy may be enrolled per investigator's discretion.
  • Have uncontrolled hypertension or poorly controlled diabetes as defined in the protocol within the screening period and prior to study treatment.
  • Have a concurrent within 5 years prior to study enrollment except for:

    • Curatively treated basal cell or squamous cell carcinoma of the skin.
    • Curatively treated cervical cancer in-situ.
    • Curatively treated superficial or non-invasive bladder cancer.
    • Curatively treated ductal or lobular breast carcinoma in situ and not currently receiving any systemic therapy.
    • Localized prostate cancer that has been treated surgically with curative intent and presumed cured.
    • Localized papillary carcinoma of thyroid that has been treated surgically with curative intent and presumed cured.
  • Have had an unstable thrombotic event (e.g., deep vein thrombosis, arterial thrombosis, pulmonary embolism) requiring therapeutic intervention within 3 months.
  • Have known infection or known acquired immunodeficiency syndrome (exceptions apply).
  • Have an active virus (HBV) infection (chronic or acute; defined as having a positive hepatitis B surface antigen test result at screening). However, participants with known HBV infection or resolved HBV infection (defined as the presence of hepatitis B core antibody and absence of hepatitis B surface antigen) are eligible only if they are negative for HBV deoxyribonucleic acid (DNA) (HBV viral load is below the limit of quantification per local laboratory).
  • Have an active virus (HCV) infection. Participants with a negative HCV antibody test at screening or positive HCV antibody test followed by a negative HCV ribonucleic acid test at screening are eligible. Participants who have completed curative antiviral treatment with HCV viral load below the limit of quantification are allowed.
  • Have received systemic corticosteroids, (s) or drugs within protocol-specified requirements prior to study treatment.
  • Have active tuberculosis or an active syphilis infection.

NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
207 participants (estimated)

Study arms

  • Experimental
    Part A (dose escalation) - BNT3219 monotherapy

    Up to 7 dose levels of BNT3219

    Drug: BNT3219

  • Experimental
    Part A (dose expansion) - BNT3219 monotherapy

    The RP2D dose level will be determined from the dose escalation in Part A

    Drug: BNT3219

Interventions

  • DrugBNT3219

    Solution for intravenous (IV) infusion

06

What researchers measure

Primary outcomes

  1. Occurrence of dose-limiting toxicities (dose escalation only)

    During the dose-limiting toxicity evaluation period. Per cohort.

    Time frame: Up to 21 days from the initiation of first dose of investigational medicinal product (IMP)

  2. Number and percentage of participants with treatment emergent adverse events (TEAEs) by TEAEs by National Cancer Institute Common Terminology Criteria for Adverse Events grading, seriousness, and relatedness

    Per cohort.

    Time frame: From the time of dosing until 90 days after the last dose of IMP

  3. Number and percentage of participants with dose interruptions, or discontinuations of study treatment due to TEAEs

    Per cohort.

    Time frame: From the first until the last dose of study treatment (up to approximately 30 months)

  4. Objective response rate (dose expansion only)

    Defined as the proportion of participants with confirmed complete response (CR) or partial response (PR) (per the Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] based on the investigator's assessment) as best overall response.

    Time frame: Up to 60 months

Secondary outcomes

  1. Pharmacokinetic (PK) assessment: Area under the curve (AUC) derived from serum concentrations of BNT3219

    After single- and multiple-dosing. Per cohort. As data permits.

    Time frame: Up to approximately 90 days after the last dose of IMP

  2. PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT3219

    After single- and multiple-dosing. Per cohort. As data permits.

    Time frame: Up to approximately 90 days after the last dose of IMP

  3. PK assessment: Time to reach maximum (peak) serum concentration (Tmax) derived from serum concentrations of BNT3219

    After single- and multiple-dosing. Per cohort. As data permits.

    Time frame: Up to approximately 90 days after the last dose of IMP

  4. PK assessment: Elimination half-life (t1/2) derived from serum concentrations of BNT3219

    After single- and multiple-dosing. Per cohort. As data permits.

    Time frame: Up to approximately 90 days after the last dose of IMP

  5. Anti-drug antibody (ADA) prevalence

    Defined as the proportion of participants who are ADA positive (either baseline or post baseline). Per cohort. As data permits.

    Time frame: Up to 90 days from the last dose of IMP

  6. ADA incidence

    Defined as the proportion of participants having treatment-emergent ADA. Per cohort. As data permits.

    Time frame: Up to 90 days from the last dose of IMP

  7. Objective response rate (dose escalation only)

    Defined as the proportion of participants in whom a confirmed CR or PR (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] based on the investigator's assessment) is observed as best overall response. Per cohort.

    Time frame: Up to 60 months

  8. Disease control rate

    Defined as the proportion of participants in whom confirmed CR, PR, or stable disease (per RECIST v1.1 based on the investigator's assessment) is observed as best overall response. Per cohort.

    Time frame: Up to 60 months

  9. Duration of response

    Defined as the time from first confirmed objective response (CR or PR based on investigator's assessment per RECIST v1.1) to first occurrence of objective tumor progression (progressive disease based on investigator's assessment per RECIST v1.1) or death from any cause, whichever occurs first. Per cohort.

    Time frame: Up to 60 months

  10. Time to response

    Defined as the time from first dose of study treatment to first confirmed objective response (CR or PR per RECIST v1.1 based on the investigator's assessment) in participants with a confirmed objective response. Per cohort.

    Time frame: Up to 60 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jul 2029, 32 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2026
First posted
Oct 23, 2026
StartEst.
Nov 2026
Primary completionEst.
Jul 2029
CompletionEst.
Oct 2030
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07893054
Lead sponsor
BioNTech SE
Collaborators
BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Oct 23, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jul 2029 (estimated)
Completion
Oct 2030 (estimated)
Last update
Oct 23, 2026

Study contacts

BioNTech clinical trials patient information
Contact
patients@biontech.de
+49 6131 9084 ext. 0
BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion